In San Francisco this week , Mr. Wilkinson said he had received interest the company 20 " high grade " a clinical trialThe drug , if approved , would be the first to treat a San Francisco this week sclerosis .But he was also    noting wryly Mr. Quinn Innate was such Mr. Wilkinson bottom feeder Mr. Wilkinson at the JPMorgan conference that the company had not even qualified for an invitation to attend the main event . 
 